Article

Segment 5 - Emerging Agents

It is an exciting time for prostate cancer due to the growth in new treatments. Dr George said that it is, in fact, both exciting and daunting to have all of these new agents being developed. Currently, there is a shortage in data for practitioners in using the new agents in sequence or combination.

It is an exciting time for prostate cancer due to the growth in new treatments. Dr George said that it is, in fact, both exciting and daunting to have all of these new agents being developed. Currently, there is a shortage in data for practitioners in using the new agents in sequence or combination. Dr George points out that all of the new therapies are based on an overall survival improvement, which is different from other cancer fields. He uses melanoma as an example where drugs are approved based upon a prolongation of survival of a small subset of patients. “Here, we are seeing improvements in the median survival of a broad unselected patient population of castration-resistant prostate cancer,” said Dr George.

Related Videos
Susan Escudier, MD, FACP
Screenshot of an interview with Evangelia Vlachou, MD
Screenshot of an interview with Barry Goy, MD
Debra Patt, MD, PhD, MBA, MPH
Clayton Irvine, PharmD, MBA, MS.
Debra Patt, MD, PhD, MBA, MPH
Debra Patt, MD, PhD, MBA, MPH
Chelsee Jensen, PharmD, BCPS.
Kara Kelly, MD, chair of pediatrics, Roswell Park Oishei Children's Cancer and Blood Disorders Program
Sandra Cuellar, PharmD
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo